In November 2023, a group of 35 rare cancer-focused academic leaders, regulatory experts, foundations, and patient advocacy groups convened a workshop to examine the issues and opportunities for rare cancer. and to imagine a path forward towards effective treat­ments and cures for rare cancer patients. 

ARC (Alliance for Rare Cancers) is an unprecedented alliance formed as a result of this workshop. Rare cancer leaders from across the U.S. have signaled they are ready to commit to radical rare cancer collaboration: to collaborate at unprecedented scale to make data-driven approaches in rare cancer a reality.

...a world where every patient diagnosed with any cancer will quickly have access to a data-driven, clinically proven approach to treatment. The promise of data-driven cancer therapy has engendered hope that, at the time of diagnosis, the molecular profile of a patient’s tumor will reliably reveal a tumor’s vulnerabilities and guide a patient’s options for treatment. Data-driven therapy can and should be available for every rare cancer patient, no matter where they live and no matter how rare their specific cancer diagnosis.

Never has this level of collaboration been undertaken in rare cancers, but the promise of  data-driven therapies finally reaching our patients has galvanized this community into action. We have begun to share our vision and additional key players in the ecosystem have joined our "coalition of the willing," donating their time and offering to commit resources to this endeavor.

Join us for an unprecedented opportunity to forge a direct path to ending rare cancer as we know it. With a shared vision, our coalition is determined to chart that path by integrating and scaling the best solutions for rare cancer challenges across the discovery, development, and care delivery systems.